3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Completed
7
Terminated
2
Recruiting
2
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
11
Endocrine
11
Thoracic
4
Gynecologic
4
Gastrointestinal
2
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
882
Pancreatic Neoplasms
573
Carcinoma, Hepatocellular
543
Stomach Neoplasms
513
Esophageal Neoplasms
312
Rectal Neoplasms
282
Colonic Neoplasms
255
Breast Neoplasms
204
Neoplasms
201
Liver Neoplasms
187
Lung Neoplasms
175
Carcinoma, Non-Small-Cell Lung
175
Cholangiocarcinoma
152
Ovarian Neoplasms
142
Neoplasm Metastasis
137
Gastrointestinal Neoplasms
134
Esophageal Squamous Cell Carcinoma
130
Melanoma
103
Prostatic Neoplasms
99
Biliary Tract Neoplasms
95
Endometrial Neoplasms
83
Uterine Cervical Neoplasms
79
Head and Neck Neoplasms
72
Squamous Cell Carcinoma of Head and Neck
69
Carcinoma, Renal Cell
58
Sarcoma
55
Adenocarcinoma Of Esophagus
54
Urinary Bladder Neoplasms
53
Anus Neoplasms
52
Triple Negative Breast Neoplasms
48
Interventions
zimberelimab
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Thyroid Carcinoma, Anaplastic
×
Gastrointestinal
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled